GSK and Curevac have announced the restructuring of their existing partnership into a new licensing agreement which will see GSK take full control of the development and manufacturing of mRNA vaccine candidates.
The strategic move allows both companies to concentrate their investment and development efforts on their respective mRNA technology platforms.
Go deeper with GlobalData
The companies partnered in 2020 to develop mRNA vaccines for infectious diseases.
Through this deal, they are now advancing vaccine candidates for seasonal influenza, Covid-19 and avian influenza.
GSK will have worldwide commercialisation rights for vaccine candidates which are currently in Phase II for seasonal influenza and Covid-19, and in Phase I for avian influenza.
The vaccines utilise CureVac’s second-generation mRNA backbone, with data indicating their potential to lead the market as new vaccines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCureVac is entitled to an upfront payment of €400m ($429.2m) and could earn up to €1.05bn on meeting development, regulatory and sales milestones.
The deal also includes tiered royalties for CureVac.
The new arrangement supersedes all financial terms from the previous collaboration between the two companies.
GSK chief scientific officer Tony Wood stated: “We are excited about our flu/Covid-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care.
“With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace.”
CureVac will retain the sole rights to other undisclosed infectious disease targets that were part of the previous partnership.
The company also maintains the freedom to develop and partner its mRNA vaccines independently in any other infectious disease or indication.
In July 2023, Curevac asserted an intellectual property right claim for mRNA technology in addition to those previously filed that are part of ongoing litigation with Pfizer/BioNTech in two jurisdictions.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
